New analysis highlights prevalence of cognitive impairment and changes in breast cancer patients

NewsGuard 100/100 Score

A recent analysis of published studies estimates that one-quarter of adults with breast cancer have cognitive impairment before starting therapy. The analysis, which is published in Psycho-Oncology, also found that many patients' cognitive function declines after receiving chemotherapy, endocrine therapy, and/or hormone therapy for breast cancer.

Our results suggest that cancer-related and personal factors may make a significant contribution to cognitive functioning."

Aicha Dijkshoorn, Study Lead Author, University Medical Center Utrecht, Netherlands

The authors noted that the findings from different studies were quite diverse, and some even reported cognitive improvements in patients after treatment. They stressed the importance of evaluating and addressing cognitive function, ideally over time, in patients with breast cancer.

World Cancer Day is February 4th.

Source:
Journal reference:

Dijkshoorn, A. B. C., et al. (2021) Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies. Wiley. doi.org/10.1002/pon.5623.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment